Jan 06,2022

Smileyscope Receives US Patent For Groundbreaking Innovations In Virtual Reality And Augmented Reality

Smileyscope Holding Inc announced the US Patent and Trade Office has awarded a patent for its innovative approach to synchronizing procedures with Virtual Reality/Augmented Reality (VR/AR) stimuli. Smileyscope, a global pioneer in VR/AR digital therapeutics, merges evidence-based medicine with state-of-the-art technology, creating ground-breaking digital treatments that help patients manage pain, anxiety, and mental health.

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Jan 12,2022

How interoperability, increased reimbursement options will drive digital health in 2022

The digital health industry experienced a big growth year in 2021. According to Rock Health’s third quarter analysis of the space, funding had already reached $21.3 billion across 541 deals. The year surpassed 2020’s full-year funding total after the second quarter.

#rpm

#telehealth

#connected device

View Analyst & Ambassador Comments
Go to original news
Jan 21,2022

What’s next for AppliedVR after its FDA De Novo

Late last year, virtual reality therapeutic company AppliedVR scored FDA De Novo clearance for its EaseVRx system for treating chronic lower back pain. The system uses regulation and mindfulness skills, as well as techniques from cognitive behavioral therapy, to help patients control their physical symptoms alongside other mental and social health problems.

#virtual reality

#cbt

View Analyst & Ambassador Comments
Go to original news
Jan 21,2022

Digital health startups pulled in record-breaking $57.2B in 2021

Digital health investment around the world hit an all-time high of $57.2 billion in funding in 2021, fueled by the growing need to provide digital solutions and delivery models to patients during the pandemic. Digital therapeutics (DTx) startups secured a record-breaking $3.4 billion across 122 deals in 2021, up 133% from the prior year.

#telehealth

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jan 26,2022

Oklahoma Health Care Authority and Pear Therapeutics Enter into Value-Based Agreement for reSET® and reSET-O®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the parent company of Pear Therapeutics (US), Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today a value-based agreement with Oklahoma Health Care Authority (OHCA) to provide access to Pear’s PDTs reSET® and reSET-O® to help fight the growing substance and opioid addiction crisis. Effective January 1, 2022, reSET and reSET-O will be made available to Oklahomans enrolled in Oklahoma Medicaid, commonly known as SoonerCare. Pear’s products reSET and reSET-O are the first and only FDA-authorized, safe and effective PDTs for the treatment of substance use disorder and opioid use disorder, respectively.

COLLABORATION PARTNERSHIP

#insurance

#reimbursement

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 02,2022

Patients Receiving Virta’s Diabetes Reversal Treatment See Sustained Reduction in Depressive Symptoms, New Research Shows

Virta Health, the leader in type 2 diabetes reversal, announced promising results on the impact of its diabetes reversal treatment on depressive symptoms. The research, published in The Journal of Behavioral Medicine, highlights rapid and sustained improvement in depressive symptoms during treatment, with nearly one-third fewer patients meeting the clinical cutoff for depression at two years.

CLINICAL STUDY

#telehealth

#virtual care

View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

Characteristics of Mobile Health Platforms for Depression and Anxiety: Content Analysis Through a Systematic Review of the Literature and Systematic Search of Two App Stores

Mobile health (mHealth) platforms show promise in the management of mental health conditions such as anxiety and depression. This has resulted in an abundance of mHealth platforms available for research or commercial use. The objective of this review is to characterize the current state of mHealth platforms designed for anxiety or depression that are available for research, commercial use, or both.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Feb 08,2022

Digital therapy aims to help teens fight depression

Many Americans have been battling mental health throughout the Covid-19 pandemic, but doctors are hoping a new tool can help struggling teens through their smartphones. Chief Science Officer at Limbix, Dr. Jessica Lake, joins News NOW to explain how her company’s digital therapy aims to help teens that are fighting depression.

View Analyst & Ambassador Comments
Go to original news
Feb 24,2022

NHS LANARKSHIRE PROMOTES MIND MATTERS WEBSITE

NHS Lanarkshire is raising awareness of Lanarkshire Mind Matters which puts high-quality mental health self-help at people's fingertips. Lanarkshire Mind Matters offers free resources to help people with anxiety, depression and sleep issues. They include SilverCloud, Big Health's Daylight and Sleepio, and CBT courses from Beating The Blues.

PRODUCT

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 01,2022

New Study Finds Cancer-Related Anxiety and Depression are Costing Medicare $5B Annually

Blue Note Therapeutics announces findings of new study highlighting the financial impacts of cancer-related anxiety and depression in Medicare beneficiaries. The study, which included over 230,000 Medicare patients, found that the incremental healthcare costs of cancer-related anxiety and depression are estimated to be nearly $17,500 per patient annually. This corresponds to a greater than 75 percent premium on the cost of cancer care for patients with anxiety and depression compared to those without.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH